| __timestamp | Amphastar Pharmaceuticals, Inc. | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 10337679 |
| Thursday, January 1, 2015 | 46974000 | 18187286 |
| Friday, January 1, 2016 | 47298000 | 24758063 |
| Sunday, January 1, 2017 | 50918000 | 23666957 |
| Monday, January 1, 2018 | 58044000 | 30099855 |
| Tuesday, January 1, 2019 | 63109000 | 64947625 |
| Wednesday, January 1, 2020 | 65157000 | 186363444 |
| Friday, January 1, 2021 | 68920000 | 272611040 |
| Saturday, January 1, 2022 | 66592000 | 358782000 |
| Sunday, January 1, 2023 | 80393000 | 409864000 |
Igniting the spark of knowledge
In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Amphastar Pharmaceuticals, Inc. and Intra-Cellular Therapies, Inc. have taken distinct paths in this regard over the past decade.
From 2014 to 2023, Amphastar maintained a relatively stable SG&A expense growth, averaging around $58 million annually, with a modest increase of approximately 99% over the period. In contrast, Intra-Cellular Therapies saw a dramatic rise in SG&A costs, skyrocketing by nearly 3,900% from 2014 to 2023. This surge reflects their aggressive expansion and investment in marketing and administrative capabilities.
While Amphastar's steady approach suggests a focus on cost control, Intra-Cellular's strategy indicates a bold push for market presence. Investors and industry analysts should consider these trends when evaluating the companies' financial health and strategic direction.
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Intra-Cellular Therapies, Inc.
SG&A Efficiency Analysis: Comparing Regeneron Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of GSK plc and Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. vs Summit Therapeutics Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and Bio-Techne Corporation
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Ascendis Pharma A/S
Intra-Cellular Therapies, Inc. and TG Therapeutics, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Intra-Cellular Therapies, Inc. vs Verona Pharma plc
Intra-Cellular Therapies, Inc. vs ADMA Biologics, Inc.: SG&A Expense Trends
Intra-Cellular Therapies, Inc. vs Xencor, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Grifols, S.A. vs Amphastar Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Amphastar Pharmaceuticals, Inc. and Evotec SE